Commentary
The concept of "rational polypharmacy" is an oft-cited, frequently lauded, yet rather inadequately proven goal of contemporary epilepsy treatment. Despite the introduction of a number of new antiepileptic drugs (AEDs) during the past 20 years, one statistic remains stubbornly unchanged; approximately one-third of our patients will continue to have seizures despite aggressive treatment with monotherapy. Given this reality, there has been renewed interest in understanding and designing effective AED regimens utilizing two (or more) medications (1, 2) .
The principle underlying rational polypharmacy is that the combination of two medications with differing mechanisms of action may result in supra-additive or synergistic anticonvulsant effects, with infra-additive toxicity (2) . This approach also requires that candidate drugs have compatible pharmacokinetic profiles (3) . Perhaps just as important, this concept also has the potential to inform the clinician of "irrational" polypharmacy (in other words, combinations of AEDs that yield antagonistic effects on seizures, or perhaps supra-additive adverse effects). The rational polypharmacy approach, therefore, clearly requires that we have a detailed and complete understanding of not only individual drug's neuropharmacologic mechanisms, but also of how the interaction with specific molecular targets impacts neuronal networks in individual patients. At its most basic level, this would seem to be an entirely simple, straightforward therapeutic approach. Unfortunately, to date, there is relatively little clinical evidence supporting this notion.
How then might we prove, or disprove, this concept. It would seem that there are four reasonable experimental approaches: 1) in vivo experiments using animal models, 2) post hoc analysis of randomized, controlled clinical trials, 3) retrospective analysis of clinical experience, and 4) prospective clinical trials based upon rational polytherapy. 
Seeking the Rational (or at least avoiding the irrational)
With respect to in vivo studies, an impressive body of experimental literature using isobolographic analysis does exist. There are two distinct methodologies for investigating potential drug combinations for both efficacy and toxicity. Type I isobolographic analysis evaluates drug combinations using the presumed effective doses of the medications, while type II analysis uses the effective dose of one drug along with a subthreshold dose of the second agent (4-6). While it is beyond the scope of this article to review these studies in depth, they support the general notion that combining AEDs with differing mechanisms will have a greater likelihood of producing synergistic effects, while combinations of agents with similar pharmacology are not only less likely to result in synergistic positive effects, but also run the risk of producing additive negative effects. .More worrisome is the observation that combinations of drugs with similar mechanisms might actually produce antagonistic interactions (4).
Experimental observations suggest that synergistic effects are seen more commonly with combinations of Na+ or Ca++ channel blockers and modulators of GABA, as well as combinations including the SV2A modulator, levetiracetam. Conversely, combinations of drugs with similar mechanisms such as Na+ channel blockade or GABA enhancement might not always result in additive effects and can, in fact, result in antagonistic interactions.
While intriguing, these experiments in animals cannot provide us with the entire clinical picture, nor can they substitute for clinical trials. For example, isobolographic analysis of lacosamide (an agent that works via enhancing slow inactivation of Na+ channels) displays synergism with other Na+ blocking AEDs, while not enhancing neurotoxic effects in mice. Data from clinical trials meanwhile, while supporting that the addition of lacosamide to conventional Na+ blocking drugs can be efficacious, also suggest an increase in CNS adverse effects when these same combinations are employed (7) .
Although data are sparse, there are data from clinical trials that suggest that particular combinations of drugs with differing mechanisms of action, such as sodium valproate and lamotrigine (8-9) may indeed display clinical synergism. Again, while intriguing, we need more evidence. Unfortunately, clinical trials designed for regulatory purposes are not prospectively designed to specifically evaluate the role of the AED mechanism of action with respect to clinical outcome. Lacking such class I trials, what other evidence is available to the clinician?
One approach would be to retrospectively evaluate AED-use patterns in a large, diverse population of patients and providers, as is reported here by Margolis and colleagues. While reports using prescription claims' databases are not unique, this particular study is. As the authors note, the approach of looking at drug-use patterns sorted by mechanism of action is novel. The hypothesis being tested here is that AED combinations involving drugs with different mechanisms (i.e., "rational polytherapy") will demonstrate improved patient outcomes as compared with combinations of drugs with similar mechanisms (i.e., "irrational polytherapy"). While this stratification is straightforward, assessment of clinical outcome is not. Margolis and coworkers propose that in adult patients, a surrogate marker of overall treatment effectiveness (efficacy + tolerability) will be persistence on therapy. The idea being that if a given AED combination was either not improving seizure control or causing excessive adverse effects, then clinicians would naturally discontinue that particular combination. An additional marker of effectiveness used was consumption of healthcare resources including hospital admissions, emergency department visits, and physician office visits. Given that it is impossible to quantitate seizure frequency with these types of data, these are reasonable surrogate measures.
In this evaluation, AEDs were classed as Na+ blockers, GABAergic drugs, SV2A modulators, or mixed mechanisms. In those patients receiving combinations solely of GABAergic drugs, or solely of Na+ blockers, persistence was the shortest as compared with those receiving combinations of AEDs with differing primary mechanisms. In particular, combinations including levetiracetam (SV2A) demonstrated significantly longer persistence as compared with single-mechanism combinations.
With respect to consumption of resources, patients receiving combinations consisting solely of Na+ blockers or GABAergic drugs saw their physician more frequently, had more emergency room visits, and had more hospital admissions as compared with those patients taking AEDs with differing mechanisms. Taken together, this naturalistic observation would seem to support the notion of rational polytherapy across a very broad patient population. Of course, there is much we still do not know. We don't know with any certainty how prescriber preference, knowledge of individual AEDs, or the quality of clinical evaluation played into the ultimate selection and continuation of AED combinations. Further, there is much we don't know about patient characteristics in this cohort, nor are the data granular enough to tease out specific drug combinations for specific seizure types. It is interesting that patients receiving at least one GABAergic drug had the greatest number of comorbidities, with the most common being depression, anxiety, fibromyalgia, and hyperlipidemia. Given that the grouping of GABAergic medicines included gabapentin, pregabalin, and several benzodiazepines, this finding is not altogether surprising and may reflect prescriber selection bias.
Despite the limitations of this type of approach, this analysis of over 8,000 patients with partial-onset epilepsy was quite consistent with data generated from animal studies. Does this study provide definitive proof of rational polytherapy? No. The population studied, outcome measures, and specifics of the AED regimens are just too broad to render precise judgments. Does it provide us with an important proof of principle? Perhaps. Using proxy measures of treatment effectiveness, these data suggest that for whatever reason, be it improved efficacy or tolerability, polytherapy with AEDs of different mechanisms provides an advantage. Perhaps now, we finally have the clinical evidence needed to construct a prospective, controlled clinical trial with well-defined, quantifiable outcome measures that can finally allow for true, evidence-based, rational polytherapy.
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